Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compressi… (NCT04067505) | Clinical Trial Compass
UnknownPhase 3
Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study
China224 participantsStarted 2020-05-18
Plain-language summary
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban for the prevention of deep vein thrombosis in patients with left iliac vein compression treated with stent implantation.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with thrombotic left iliac vein compression syndrome who underwent left iliac vein stent implantation
Exclusion Criteria:
* Age \< 18 years or age \> 75 years
* With history of pelvic surgery, left iliac vein trauma and pelvic radiotherapy
* With obvious contraindications for anticoagulation therapy
* Allergic to iodine contrast agents in the past
* With concomitant diseases that need high-intensity anticoagulation, and the anticoagulation intensity is clearly higher than that of the patients with iliac vein therapy alone
* Active bleeding or potential bleeding risk
* Pregnant or breastfeeding women
* With pelvic tumors causing compression of left iliac vein,
* With chronic venous insufficiency of lower extremities caused by K-T syndrome
* With malignant tumors and life expectancy \< 1 year
* Taking cytochrome P450 3A4(CYP-450 3A4) inhibitors or inducers
What they're measuring
1
stent occlusion rate
Timeframe: 2 year after operation
Trial details
NCT IDNCT04067505
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University